Literature DB >> 28215999

Rat animal models for screening medications to treat alcohol use disorders.

Richard L Bell1, Sheketha R Hauser2, Tiebing Liang3, Youssef Sari4, Antoniette Maldonado-Devincci5, Zachary A Rodd2.   

Abstract

The purpose of this review is to present animal research models that can be used to screen and/or repurpose medications for the treatment of alcohol abuse and dependence. The focus will be on rats and in particular selectively bred rats. Brief introductions discuss various aspects of the clinical picture, which provide characteristics of individuals with alcohol use disorders (AUDs) to model in animals. Following this, multiple selectively bred rat lines will be described and evaluated in the context of animal models used to screen medications to treat AUDs. Next, common behavioral tests for drug efficacy will be discussed particularly as they relate to stages in the addiction cycle. Tables highlighting studies that have tested the effects of compounds using the respective techniques are included. Wherever possible the Tables are organized chronologically in ascending order to describe changes in the focus of research on AUDs over time. In general, high ethanol-consuming selectively bred rats have been used to test a wide range of compounds. Older studies usually followed neurobiological findings in the selected lines that supported an association with a propensity for high ethanol intake. Most of these tests evaluated the compound's effects on the maintenance of ethanol drinking. Very few compounds have been tested during ethanol-seeking and/or relapse and fewer still have assessed their effects during the acquisition of AUDs. Overall, while a substantial number of neurotransmitter and neuromodulatory system targets have been assessed; the roles of sex- and age-of-animal, as well as the acquisition of AUDs, ethanol-seeking and relapse continue to be factors and behaviors needing further study. This article is part of the Special Issue entitled "Alcoholism".
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AA; Acamprosate (PubChem CID: 71158); Alcohol use disorder; Alcoholism; Baclofen (PubChem CID: 2284); Ceftriaxone (PubChem CID: 5479530); Ethanol (PubChem CID: 702); Family history positive; Fluoxetine (PubChem CID: 3386); Genetically predisposed; HAD; Naltrexone (PubChem CID: 5360515); P; Pharmacotherapy; Prazosin (PubChem CID: 4893); Rolipram (PubChem CID: 5092); Selectively bred; Topiramate (PubChem CID: 5284627); UChB; Varenicline (PubChem CID: 5310966); WHP; msP; sP

Mesh:

Substances:

Year:  2017        PMID: 28215999      PMCID: PMC5659204          DOI: 10.1016/j.neuropharm.2017.02.004

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  566 in total

1.  Chronic tolerance and sensitization to alcohol in sons of alcoholics: II. Replication and reanalysis.

Authors:  D B Newlin; J B Thomson
Journal:  Exp Clin Psychopharmacol       Date:  1999-08       Impact factor: 3.157

2.  Long-term alcohol self-administration with repeated alcohol deprivation phases: an animal model of alcoholism?

Authors:  R Spanagel; S M Hölter
Journal:  Alcohol Alcohol       Date:  1999 Mar-Apr       Impact factor: 2.826

3.  The delta 2-opioid receptor antagonist naltriben reduces motivated responding for ethanol.

Authors:  H L June; S R McCane; R W Zink; P S Portoghese; T K Li; J C Froehlich
Journal:  Psychopharmacology (Berl)       Date:  1999-11       Impact factor: 4.530

4.  Effects of naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol seeking induced by priming injections of alcohol and exposure to stress.

Authors:  A D Lê; C X Poulos; S Harding; J Watchus; W Juzytsch; Y Shaham
Journal:  Neuropsychopharmacology       Date:  1999-09       Impact factor: 7.853

5.  Antidepressant-like effect of ethanol revealed in the forced swimming test in Sardinian alcohol-preferring rats.

Authors:  R Ciccocioppo; I Panocka; R Froldi; G Colombo; G L Gessa; M Massi
Journal:  Psychopharmacology (Berl)       Date:  1999-05       Impact factor: 4.530

6.  Naloxone retards the expression of a genetic predisposition toward alcohol drinking.

Authors:  N E Badia-Elder; A K Mosemiller; R L Elder; J C Froehlich
Journal:  Psychopharmacology (Berl)       Date:  1999-06       Impact factor: 4.530

Review 7.  Craving and relapse measurement in alcoholism.

Authors:  A S Potgieter; F Deckers; P Geerlings
Journal:  Alcohol Alcohol       Date:  1999 Mar-Apr       Impact factor: 2.826

Review 8.  Animal models of alcoholism: neurobiology of high alcohol-drinking behavior in rodents.

Authors:  W J McBride; T K Li
Journal:  Crit Rev Neurobiol       Date:  1998

9.  Ethanol induces conditioned place preference in genetically selected alcohol-preferring rats.

Authors:  R Ciccocioppo; I Panocka; R Froldi; E Quitadamo; M Massi
Journal:  Psychopharmacology (Berl)       Date:  1999-01       Impact factor: 4.530

10.  Effects of repeated withdrawal from chronic ethanol on oral self-administration of ethanol on a progressive ratio schedule.

Authors:  G Brown; A Jackson; D N Stephens
Journal:  Behav Pharmacol       Date:  1998-03       Impact factor: 2.293

View more
  29 in total

1.  The future is now: A 2020 view of alcoholism research.

Authors:  R Adron Harris; George F Koob
Journal:  Neuropharmacology       Date:  2017-08-01       Impact factor: 5.250

Review 2.  From gene networks to drugs: systems pharmacology approaches for AUD.

Authors:  Laura B Ferguson; R Adron Harris; Roy Dayne Mayfield
Journal:  Psychopharmacology (Berl)       Date:  2018-03-01       Impact factor: 4.530

3.  High Drinking in the Dark (HDID) mice are sensitive to the effects of some clinically relevant drugs to reduce binge-like drinking.

Authors:  John C Crabbe; Angela R Ozburn; Pamela Metten; Amanda Barkley-Levenson; Jason P Schlumbohm; Stephanie E Spence; Wyatt R Hack; Lawrence C Huang
Journal:  Pharmacol Biochem Behav       Date:  2017-08-05       Impact factor: 3.533

4.  CIS-Acting Allele-Specific Expression Differences Induced by Alcohol and Impacted by Sex as Well as Parental Genotype of Origin.

Authors:  Chiao-Ling Lo; Lawrence Lumeng; Richard L Bell; Tiebing Liang; Amy C Lossie; Williams M Muir; Feng C Zhou
Journal:  Alcohol Clin Exp Res       Date:  2018-06-09       Impact factor: 3.455

5.  Cessation of fluoxetine treatment increases alcohol seeking during relapse and dysregulates endocannabinoid and glutamatergic signaling in the central amygdala.

Authors:  Juan Suárez; Sophia Khom; Francisco Alén; Luis A Natividad; Florence P Varodayan; Reesha R Patel; Dean Kirson; Rocío Arco; Antonio Ballesta; Michal Bajo; Leticia Rubio; Rémi Martin-Fardon; Fernando Rodríguez de Fonseca; Marisa Roberto
Journal:  Addict Biol       Date:  2019-07-24       Impact factor: 4.280

6.  Evidence for Modulation of Substance Use Disorders by the Gut Microbiome: Hidden in Plain Sight.

Authors:  Mariana Angoa-Pérez; Donald M Kuhn
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

Review 7.  Potential of GABAB Receptor Positive Allosteric Modulators in the Treatment of Alcohol Use Disorder.

Authors:  Paola Maccioni; Giancarlo Colombo
Journal:  CNS Drugs       Date:  2019-02       Impact factor: 5.749

8.  Spontaneous Early Withdrawal Behaviors after Chronic 24-hour Free-Choice Access to Ethanol.

Authors:  Sheketha R Hauser; Rebecca J Smith; Jamie E Toalston; Zachary A Rodd; William J McBride; Richard L Bell
Journal:  Alcohol Alcohol       Date:  2020-08-14       Impact factor: 2.826

9.  Naltrexone alters alcohol self-administration behaviors and hypothalamic-pituitary-adrenal axis activity in a sex-dependent manner in rats.

Authors:  Steven J Nieto; Cana B Quave; Therese A Kosten
Journal:  Pharmacol Biochem Behav       Date:  2018-02-24       Impact factor: 3.533

10.  Sex Differences in Motivation to Self-Administer Alcohol After 2 Weeks of Abstinence in Young-Adult Heavy Drinkers.

Authors:  Martin Henry Plawecki; Kurt White; Ann E K Kosobud; Nicholas Grahame; Ulrich S Zimmermann; David Crabb; Sean O'Connor
Journal:  Alcohol Clin Exp Res       Date:  2018-08-29       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.